LAURUS LABS Financial Statement Analysis
|
||
|
The Revenues of LAURUS LABS have increased by 10.18% YoY .
The Earnings Per Share (EPS) of LAURUS LABS has increased by 147.89 % YoY. |
||
LAURUS LABS Last 5 Annual Financial Results
[BOM: 540222|NSE : LAURUSLABS]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹5,554 Cr | ₹5,041 Cr | ₹6,041 Cr | ₹4,936 Cr | ₹4,814 Cr |
| Expenses | ₹4,499 Cr | ₹4,263 Cr | ₹4,448 Cr | ₹3,513 Cr | ₹3,263 Cr |
| Operating Profit (Excl OI) | ₹1,055 Cr | ₹778 Cr | ₹1,592 Cr | ₹1,422 Cr | ₹1,551 Cr |
| Other Income | ₹75 Cr | ₹26 Cr | ₹6.00 Cr | ₹15 Cr | ₹24 Cr |
| Interest | ₹216 Cr | ₹183 Cr | ₹165 Cr | ₹102 Cr | ₹68 Cr |
| Depreciation | ₹430 Cr | ₹385 Cr | ₹324 Cr | ₹251 Cr | ₹205 Cr |
| Profit Before Tax | ₹484 Cr | ₹236 Cr | ₹1,109 Cr | ₹1,084 Cr | ₹1,301 Cr |
| Profit After Tax | ₹354 Cr | ₹168 Cr | ₹797 Cr | ₹832 Cr | ₹984 Cr |
| Consolidated Net Profit | ₹358 Cr | ₹158 Cr | ₹785 Cr | ₹828 Cr | ₹984 Cr |
| Earnings Per Share (Rs) | ₹16.46 | ₹6.64 | ₹2.93 | ₹14.56 | ₹15.40 |
| PAT Margin (%) | 13.06 | 6.38 | 3.34 | 13.19 | 16.87 |
| ROE(%) | 18.31 | 8.30 | 4.15 | 21.63 | 28.05 |
| ROCE(%) | 18.20 | 10.16 | 6.64 | 22.97 | 25.97 |
| Total Debt/Equity(x) | 0.45 | 0.61 | 0.61 | 0.49 | 0.52 |
Key Financials |
||
| Market Cap | : | ₹ 98,061.7 Cr |
| Revenue (TTM) | : | ₹ 7,269.6 Cr |
| Net Profit(TTM) | : | ₹ 1,090.8 Cr |
| EPS (TTM) | : | ₹ 20.2 |
| P/E (TTM) | : | 89.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LAURUS LABS | -2.7% | 16.5% | 119.6% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.4% | -1.3% | 21.5% |
| DIVIS LABORATORIES | 2.7% | 16.1% | 38.6% |
| TORRENT PHARMACEUTICALS | -1.5% | -3.3% | 35.6% |
| CIPLA | -0.7% | 1.4% | -2% |
| DR REDDYS LABORATORIES | 3.9% | -1.8% | 0.4% |
| MANKIND PHARMA | -0.7% | -4.9% | -4.9% |
| LUPIN | -1.8% | -10.6% | 16.2% |
| ZYDUS LIFESCIENCES | 1.7% | -1.2% | 24.1% |
LAURUS LABS Revenues
[BOM: 540222|NSE : LAURUSLABS]
| Y-o-Y | 10.18 % |
| 5 Yr CAGR | 3.64 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹5,554 Cr | 10.18 | |
| Mar2025 | ₹5,041 Cr | -16.55 | |
| Mar2024 | ₹6,041 Cr | 22.39 | |
| Mar2023 | ₹4,936 Cr | 2.54 | |
| Mar2022 | ₹4,814 Cr | - | |
LAURUS LABS Operating Profit
[BOM: 540222|NSE : LAURUSLABS]
| Y-o-Y | 35.73 % |
| 5 Yr CAGR | -9.17 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,055 Cr | 35.73 | |
| Mar2025 | ₹778 Cr | -51.17 | |
| Mar2024 | ₹1,592 Cr | 11.93 | |
| Mar2023 | ₹1,422 Cr | -8.27 | |
| Mar2022 | ₹1,551 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 23.22 % |
| 5 Yr CAGR | -12.37 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 19% | 23.22 | |
| Mar2025 | 15.42% | -41.50 | |
| Mar2024 | 26.36% | -8.54 | |
| Mar2023 | 28.82% | -10.55 | |
| Mar2022 | 32.22% | - | |
LAURUS LABS Profit After Tax
[BOM: 540222|NSE : LAURUSLABS]
| Y-o-Y | 127.25 % |
| 5 Yr CAGR | -22.31 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹358 Cr | 127.25 | |
| Mar2025 | ₹158 Cr | -79.90 | |
| Mar2024 | ₹785 Cr | -5.20 | |
| Mar2023 | ₹828 Cr | -15.87 | |
| Mar2022 | ₹984 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 104.70 % |
| 5 Yr CAGR | -6.20 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 13.06 % | 104.70 | |
| Mar2025 | 6.38 % | 91.02 | |
| Mar2024 | 3.34 % | -74.68 | |
| Mar2023 | 13.19 % | -21.81 | |
| Mar2022 | 16.87 % | - | |
LAURUS LABS Earnings Per Share (EPS)
[BOM: 540222|NSE : LAURUSLABS]
| Y-o-Y | 147.89 % |
| 5 Yr CAGR | 1.68 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹16 | 147.89 | |
| Mar2025 | ₹6.64 | 126.62 | |
| Mar2024 | ₹2.93 | -79.88 | |
| Mar2023 | ₹15 | -5.45 | |
| Mar2022 | ₹15 | - | |
LAURUS LABS Return on Capital Employed (ROCE)
[BOM: 540222|NSE : LAURUSLABS]
| Y-o-Y | 79.13 % |
| 5 Yr CAGR | -8.50 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 18.2% | 79.13 | |
| Mar2025 | 10.16% | 53.01 | |
| Mar2024 | 6.64% | -71.09 | |
| Mar2023 | 22.97% | -11.55 | |
| Mar2022 | 25.97% | - | |
LAURUS LABS Share Price vs Sensex
| Current Share Price | : | ₹1,815.0 |
| Current MarketCap | : | ₹ 98,061.7 Cr |
| Updated EOD on | : | Aug 14,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LAURUS LABS | -2.7% |
16.5% |
119.6% |
| SENSEX | -0.6% |
1.1% |
-3.2% |
LAURUS LABS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE MIDCAP SELECT INDEX | 0.5% | 2.7% | 15.9% |
| BSE 500 MOMENTUM 50 | 0.3% | 2.8% | NA |
| BSE 150 MIDCAP INDEX | 0.2% | 1.6% | 10.4% |
| BSE 400 MIDSMALLCAP INDEX | 0% | 1.4% | 9.3% |
| BSE 1000 | -0.3% | 1.7% | 4.4% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY500 MOMENTUM 50 | 0.5% | 1.8% | 6.8% |
| NIFTY MIDCAP 100 | 0.5% | 1.3% | 12.4% |
| NIFTY MIDCAP 50 | 0.5% | 1.2% | 14.5% |
| NIFTY200 ALPHA 30 | 0.4% | 1.4% | 8.9% |
| NIFTY MIDCAP150 MOMENTUM 50 | 0.4% | 1.5% | 5.9% |
You may also like the below Video Courses
FAQ about LAURUS LABS Financials
How the annual revenues of LAURUS LABS have changed ?
The Revenues of LAURUS LABS have increased by 10.18% YoY .
How the Earnings per Share (EPS) of LAURUS LABS have changed?
The Earnings Per Share (EPS) of LAURUS LABS has increased by 147.89 % YoY .
Check out Intrinsic Value of Peers of LAURUS LABS
Compare Stock Analytics of Peers of LAURUS LABS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
